The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established because of a critical need for multi-institutional clinical trials focused directly on improving survival for patients undergoing hematopoietic cell transplantation (HCT). Since 2001, the BMT CTN has opened more than 27 multi-institutional phase II and III trials, involved more than 100 transplant centers, and enrolled thousands of patients.
BMT CTN is funded through the National Institutes of Health (NIH) and is a collaborative effort of the CIBMTR, the National Marrow Donor Program (NMDP), and the EMMES Corporation, together with 20 Core Transplant Centers. Collectively, CIBMTR, NMDP and EMMES serve as the BMT CTN Data and Coordinating Center to provide administrative, statistical, scientific and informatics support to all BMT CTN activities.
Progress through collaboration
The vision for BMT CTN by both the National Heart, Lung and Blood Institute (NHLBI), and National Cancer Institute (NCI), two institutions of the NIH, has produced an efficient and collaborative mechanism to move promising HCT therapies from phase I and II trials to definitive testing in larger, multi-center settings.
Learn more about current BMT CTN research and resources:
Visit the BMT CTN Web site to learn more about this research and how to get involved.